Black clients in expansion states who used opioids were more likely to access medication for opioid use disorder after ACA implementation.

[1]  T. Winkelman,et al.  Medicaid Expansion Increased Medications For Opioid Use Disorder Among Adults Referred By Criminal Justice Agencies. , 2021, Health affairs.

[2]  R. Sadler,et al.  African Americans now Outpace Whites in Opioid-Involved Overdose Deaths: A Comparison of Temporal Trends from 1999-2018. , 2020, Addiction.

[3]  S. Comer,et al.  Intervention in an opioid overdose event increases interest in treatment among individuals with opioid use disorder , 2020, Substance abuse.

[4]  Zachary F. Meisel,et al.  Incidence of Treatment for Opioid Use Disorder Following Nonfatal Overdose in Commercially Insured Patients , 2020, JAMA network open.

[5]  Rebecca J. Shlafer,et al.  Medications for opioid use disorder among pregnant women referred by criminal justice agencies before and after Medicaid expansion: A retrospective study of admissions to treatment centers in the United States , 2020, PLoS medicine.

[6]  B. Marshall,et al.  Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States , 2020, JAMA network open.

[7]  Darshak M Sanghavi,et al.  Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. , 2020, JAMA network open.

[8]  C. Brayne,et al.  Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17 , 2019, PloS one.

[9]  D. Polsky,et al.  Private Coverage of Methadone in Outpatient Treatment Programs. , 2019, Psychiatric services.

[10]  K. Geissler,et al.  Changes in Medicaid Acceptance by Substance Abuse Treatment Facilities After Implementation of Federal Parity , 2019, Medical care.

[11]  P. Friedmann,et al.  Medicaid coverage in substance use disorder treatment after the affordable care act. , 2019, Journal of substance abuse treatment.

[12]  M. Olfson,et al.  The Affordable Care Act and Opioid Agonist Therapy for Opioid Use Disorder. , 2019, Psychiatric services.

[13]  K. Kozhimannil,et al.  Substance use disorder treatment admissions and state-level prenatal substance use policies: Evidence from a national treatment database. , 2019, Addictive behaviors.

[14]  C. MacLean,et al.  The Effect of Public Insurance Expansions on Substance Use Disorder Treatment: Evidence from the Affordable Care Act , 2017, Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management].

[15]  T. Land,et al.  Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose. , 2020, Annals of emergency medicine.

[16]  T. Wilens,et al.  Opioid Use Disorders: Perioperative Management of a Special Population , 2018, Anesthesia and analgesia.

[17]  Na Wang,et al.  Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality , 2018, Annals of Internal Medicine.

[18]  Angélica Meinhofer,et al.  The role of health insurance on treatment for opioid use disorders: Evidence from the Affordable Care Act Medicaid expansion. , 2018, Journal of health economics.

[19]  K. Feder,et al.  Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine. , 2017, Health affairs.

[20]  Ryan M. McKenna.  Treatment use, sources of payment, and financial barriers to treatment among individuals with opioid use disorder following the national implementation of the ACA. , 2017, Drug and alcohol dependence.

[21]  K. Feder,et al.  Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. , 2017, Drug and alcohol dependence.

[22]  W. Gellad,et al.  Medication-Assisted Treatment and Opioid Use Before and After Overdose in Pennsylvania Medicaid , 2017, JAMA.

[23]  Fang Zhang,et al.  Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014 , 2017, JAMA pediatrics.

[24]  B. Madras.  The Surge of Opioid Use, Addiction, and Overdoses: Responsibility and Response of the US Health Care System. , 2017, JAMA psychiatry.

[25]  B. Druss,et al.  Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment , 2017, Medical care.

[26]  C. Horgan,et al.  Commercial Health Plan Coverage of Selected Treatments for Opioid Use Disorders from 2003 to 2014 , 2017, Journal of psychoactive drugs.

[27]  He Zhu,et al.  Treatment utilization among persons with opioid use disorder in the United States. , 2016, Drug and alcohol dependence.

[28]  J. Morenoff,et al.  Health Insurance Trends and Access to Behavioral Healthcare Among Justice-Involved Individuals—United States, 2008–2014 , 2016, Journal of General Internal Medicine.

[29]  Astha Singhal,et al.  Racial-Ethnic Disparities in Opioid Prescriptions at Emergency Department Visits for Conditions Commonly Associated with Prescription Drug Abuse , 2016, PloS one.

[30]  H. Hansen,et al.  Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. , 2016, Drug and alcohol dependence.

[31]  B. Anderson,et al.  Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification. , 2016, Journal of substance abuse treatment.

[32]  B. Cook,et al.  Access To Mental Health Care Increased But Not For Substance Use, While Disparities Remain. , 2016, Health affairs.

[33]  C. Barry,et al.  Justice-Involved Adults With Substance Use Disorders: Coverage Increased But Rates Of Treatment Did Not In 2014. , 2016, Health affairs.

[34]  J. Mennis,et al.  Racial and Ethnic Disparities in Outpatient Substance Use Disorder Treatment Episode Completion for Different Substances. , 2016, Journal of substance abuse treatment.

[35]  Colleen L Barry,et al.  Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment. , 2016, Psychiatric services.

[36]  Thomas R Frieden,et al.  Medication-assisted therapies--tackling the opioid-overdose epidemic. , 2014, The New England journal of medicine.

[37]  C. Welsh,et al.  Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone. , 2014, Drug and alcohol dependence.

[38]  W. Ling,et al.  Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. , 2014, Addiction.

[39]  B. Saloner,et al.  Blacks and Hispanics are less likely than whites to complete addiction treatment, largely due to socioeconomic factors. , 2013, Health affairs.

[40]  K. Anderson,et al.  Racial and ethnic disparities in pain: causes and consequences of unequal care. , 2009, The journal of pain : official journal of the American Pain Society.

[41]  J. Bell,et al.  Comparing overdose mortality associated with methadone and buprenorphine treatment. , 2009, Drug and alcohol dependence.

[42]  J. Strang,et al.  Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. , 2009, Journal of substance abuse treatment.

[43]  Dingcai Cao,et al.  Need-service matching in substance abuse treatment: racial/ethnic differences. , 2009, Evaluation and program planning.

[44]  M. Connock,et al.  Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. , 2007, Health technology assessment.

[45]  A. Kilbourne,et al.  Advancing health disparities research within the health care system: a conceptual framework. , 2006, American journal of public health.

[46]  Yongli Xi,et al.  Increasing deaths from opioid analgesics in the United States , 2006, Pharmacoepidemiology and drug safety.